New risk tool aims to take the guesswork out of sarcoma treatment choices
NCT ID NCT05741944
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests a tool called PERSARC that gives soft-tissue sarcoma patients personalized information about the risks and benefits of different treatment options. 120 adults with high-grade sarcoma in their arms or legs will either get standard care or care using PERSARC. The goal is to see if the tool helps patients feel more informed and less conflicted about their treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PERSARC risk prediction tool
What this could lead to
If successful, this tool could help patients and doctors make clearer, more personalized treatment decisions for soft-tissue sarcoma.
What could go wrong
This is a small, early-stage study focused on decision-making, not on curing or treating the cancer itself. The tool may not improve outcomes or be widely adopted.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOFT TISSUE SARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Erasmus MC
Rotterdam, South Holland, 3015GD, Netherlands
-
Leiden University Medical Center
Leiden, South Holland, 2333ZA, Netherlands
-
Maastricht UMC
Maastricht, Limburg, 6229HX, Netherlands
-
Netherlands Cancer Institue
Amsterdam, North Holland, 1066CX, Netherlands
-
Radboud UMC
Nijmegen, Gelderland, 6525GA, Netherlands
-
UMC Groningen
Groningen, Provincie Groningen, 9713GZ, Netherlands
-
UMC Utrecht
Utrecht, Utrecht, 3584CX, Netherlands